Cellular fats and cultured lipids
01Overview and value chain
Markers: [EC: USDA/FDA joint regulatory framework for cell-cultured animal products | OECD: Food systems | Regulator: FDA (USA)]
Cellular fats and cultured lipids grow actual animal adipose-derived cells — not a fermenting microbe standing in for animal fat — to produce a cultivated fat ingredient that blends into hybrid meat and plant-based products. Mission Barns won USDA and FDA sign-off for cultivated pork fat in 2025 and is targeting a Sprouts Farmers Market launch, using a proprietary bioreactor design intended to lower the capital intensity that has slowed whole-cut cultivated meat. Because fat cells are used as a flavor- and texture-carrying ingredient rather than a full-tissue meat replacement, the category needs far less structural scaffolding than whole-muscle cultivated meat, and academic groups have demonstrated proof-of-concept adipose-derived stem cell fat production from both bovine and duck cell lines in 3D culture. The category has already produced its own cautionary tale: CellulaREvolution, a UK originator working on bovine adipose-derived stem cell spheroids as building blocks for cultured fat, entered administration, with its IP and assets put up for sale.
Key directions of cellular fats and cultured lipids:
- Cultivated pork/duck fat (Cultivated Pork/Duck Fat): adipose-derived cells grown and harvested specifically as a fat ingredient for blended meat products, proven at lab scale for both pork and duck cell lines.
- Ingredient-scale cell culture (Ingredient-Scale Cell Culture): fat cells cultured as a flavor/texture additive rather than attempting a full structural meat replacement, lowering the scaffolding and bioreactor burden versus whole-cut cultivated meat.
- Novel bioreactor engineering for fat cells (Novel Bioreactor Engineering for Fat Cells): purpose-built, more easily scaled bioreactor designs specifically targeting fat-cell culture economics rather than adapting muscle-cell bioreactors.
- 3D spheroid biofabrication (3D Spheroid Biofabrication): building cultured fat from dynamically cultured, differentiated adipose-derived stem cell spheroids as a structural building block.
Sectoral value chain
[cell line sourcing] ──> [growth-media formulation] ──> [bioreactor cultivation] ──> [fat harvest & processing]
│
(regulatory
clearance)
│
▼
[hybrid meat product] <─── [ingredient blending] <──────────────┘Value chain levels
| Level | Description | Key inputs/outputs |
|---|---|---|
| Cell Line Sourcing | isolating adipose-derived stem cells from a target species | In: biopsy/cell bank source. Out: adipose-derived cell line. |
| Growth-Media Formulation | formulating serum-free media to differentiate and expand fat cells | In: nutrient inputs. Out: differentiation-ready medium. |
| Bioreactor Cultivation | growing fat cells or spheroids at scale in purpose-built bioreactors | In: cell line, medium. Out: cultured fat biomass. |
| Fat Harvest & Processing | separating and processing cultured fat into a usable ingredient | In: cultured fat biomass. Out: cultivated fat ingredient. |
| Regulatory Clearance | USDA/FDA joint pre-market review for a cell-cultured food ingredient | In: safety dossier. Out: market authorization. |
| Ingredient Blending | blending cultivated fat into a hybrid meat or plant-based product | In: cleared fat ingredient. Out: finished blended product. |
Cross-cutting technologies of the sector:
- Adipose-derived stem cell isolation (Adipose-Derived Stem Cell Isolation): sourcing and banking the target species’ fat-precursor cells as the production cell line.
- 3D spheroid culture (3D Spheroid Culture): growing differentiated adipose-derived cells as spheroids to serve as building blocks for structured cultured fat.
- Purpose-built fat-cell bioreactors (Purpose-Built Fat-Cell Bioreactors): bioreactor designs engineered specifically around fat-cell (rather than muscle-cell) culture economics.
02US
The US hosts the sector’s first regulatory-cleared cultivated fat product and a second cell-agriculture originator founded by an early cultivated-meat tissue-engineering researcher.
USDA/FDA joint sign-off, novel bioreactor scale-up, cultivated-meat tissue-engineering pedigree
- Mission Barns: won USDA and FDA sign-off for cultivated pork fat in 2025, developed a novel, more easily scaled bioreactor design, and is targeting a retail launch through Sprouts Farmers Market.
- Ohayo Valley: founded by Dr. Jess Krieger, one of the first researchers in the world to pursue a PhD specifically on cultivated meat tissue engineering, extending that research background into a cell-agriculture venture.
03CN
Public information on a dedicated Chinese cellular-fat/cultured-lipid originator was not confirmed in this pass; the section stays at the policy level.
no confirmed flagship originator, adjacent fermentation-fat investment, regulatory framework absent
- No confirmed flagship originator: a Chinese company operating a true animal-cell-culture fat platform (as opposed to microbial-fermentation fat production) was not confirmed via live sources in this pass.
- Adjacent fermentation-fat activity: Chinese fermentation specialists have partnered with overseas precision-fermentation fat originators, reflecting capacity and investment interest in fat alternatives generally, without a confirmed domestic cell-culture originator.
- No dedicated regulatory framework: unlike the US’s USDA/FDA joint review pathway, no China-specific cell-cultured-fat authorization framework was confirmed in this pass.
04EU
The EU/UK region shows both a growing cell-cultured-fat originator raising early funding and a cautionary example of one going into administration.
Berlin-based cultured-fat funding, UK spheroid biofabrication research, insolvency risk in early-stage cell agriculture
- Cultimate Foods: a Berlin-based originator (founded 2022) specializing in cultivating animal fat as an ingredient to improve the flavor and quality of plant-based meat, which raised €2.3 million to develop its fat ingredient.
- CellulaREvolution: a UK originator that developed dynamically cultured, differentiated bovine adipose-derived stem cell spheroids as building blocks for biofabricating cultured fat, but entered administration, with its IP and assets subsequently put up for sale.
- Early-stage capital risk: the sector’s UK example illustrates that cell-culture-based fat ventures carry meaningful insolvency risk at the pre-commercial research stage, distinct from the demand-side risk seen in industrial insect farming.
05Leading companies and research institutes
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Mission Barns | 🇺🇸 USA | Cultivated pork fat | USDA/FDA-cleared (2025); novel scalable bioreactor | Commercial |
| Cultimate Foods | 🇩🇪 Germany | Cultured fat for plant-based meat | €2.3M raised (2024); founded 2022 | Growth |
| Ohayo Valley | 🇺🇸 USA | Cell-agriculture fat platform | founded by early cultivated-meat tissue-engineering researcher | Growth |
| CellulaREvolution | 🇬🇧 UK | Bovine adipose-derived stem cell spheroids | 3D spheroid biofabrication for cultured fat | Unknown (in administration) |
06Tech stack and innovations
The stack is built around culturing fat cells as an ingredient rather than a structural meat substitute.
- Purpose-built fat-cell bioreactors (Purpose-Built Fat-Cell Bioreactors):
- bioreactor designs are engineered specifically around fat-cell culture economics rather than adapted from muscle-cell systems.
- case: Mission Barns’ novel bioreactor design is intended to lower the capital intensity that has slowed broader cultivated-meat scale-up.
- 3D adipose spheroid biofabrication (3D Adipose Spheroid Biofabrication):
- differentiated adipose-derived stem cells are dynamically cultured as spheroids that serve as structural building blocks for cultured fat.
- case: bovine adipose-derived stem cell spheroids have been demonstrated as a biofabrication building block in peer-reviewed research.
- Cross-species proof-of-concept culture (Cross-Species Proof-of-Concept Culture):
- fat-cell culture methods are being validated across multiple species’ cell lines rather than a single target animal.
- case: proof-of-concept cell-culture-based duck fat production has been demonstrated at laboratory scale alongside bovine and porcine work.
07Value chains and production pipelines
Industrial pipeline of a cultivated fat ingredient (USDA/FDA joint pre-market review)
┌───────────────────────────┐ ┌───────────────────────────┐
│ 1. Cell line sourcing │ ───> │ 2. Media formulation │
└───────────────────────────┘ └───────────────────────────┘
│
▼
┌───────────────────────────┐ ┌───────────────────────────┐
│ 4. Regulatory dossier │ <─── │ 3. Bioreactor cultivation │
└───────────────────────────┘ └───────────────────────────┘
│
▼
┌───────────────────────────┐ ┌───────────────────────────┐
│ 5. Ingredient blending │ ───> │ 6. Retail launch │
└───────────────────────────┘ └───────────────────────────┘Stage 1: Cell line sourcing
Adipose-derived stem cells are isolated and banked from the target species (pig, cattle, duck).
Stage 2: Media formulation
A serum-free growth medium is formulated to expand and differentiate the fat-precursor cells.
Stage 3: Bioreactor cultivation
Cells or spheroids are cultured at scale in a purpose-built bioreactor designed around fat-cell economics.
Stage 4: Regulatory dossier
A joint USDA/FDA pre-market safety dossier is filed and reviewed, as completed by Mission Barns in 2025.
Stage 5: Ingredient blending
The cleared cultivated fat is blended into a hybrid meat or plant-based product to carry flavor and texture.
Stage 6: Retail launch
The finished product reaches retail, as targeted through a named grocery partner in the sector’s first cleared case.
| Supplier | Price | Certificates | Risk | Confidence |
|---|---|---|---|---|
| Mission Barns | on request | Medium | MEDIUM | |
| Cultimate Foods | research | High | MEDIUM | |
| Ohayo Valley | research | High | LOW | |
| CellulaREvolution | custom | High | MEDIUM |
AI note: cellular-fats-cultured-lipids (EN)
Key directions:
- Cultivated pork/duck fat — adipose-derived cells grown as a fat ingredient, proven at lab scale for pork and duck cell lines.
- Ingredient-scale cell culture — fat cells as a flavor/texture additive, not a full structural meat replacement, lowering the scaffolding burden.
- Novel bioreactor engineering for fat cells — purpose-built designs targeting fat-cell economics specifically.
- 3D spheroid biofabrication — dynamically cultured adipose-derived stem cell spheroids as structural building blocks.
Regulatory:
- US: joint USDA/FDA pre-market review cleared Mission Barns’ cultivated pork fat in 2025 — the first regulatory milestone in true cell-cultured fat (as distinct from cultivated whole-muscle meat).
- No China-specific cell-cultured-fat authorization framework was confirmed in this pass.
Companies not in table: Cubiq Foods and Nourish Ingredients were investigated but excluded — both surfaced strongly in the search but their core technology is precision fermentation (a microbial host producing fat), not true animal cell culture, so including them here would mismap a fermentation-based company into a cell-culture-specific industry; that fermentation-fats ground is covered by the sibling biosynthetic-palm-fat article (which IND-028 was skipped as MECE against).
Processing note: this category’s defining engineering choice is scope — culturing fat cells only, as a blendable ingredient, sidesteps the vascularization and scaffolding problems that have slowed whole-cut cultivated meat, which is why Mission Barns reached a regulatory clearance in 2025 while most whole-muscle cultivated-meat companies (see the sibling cultivated-meat article) have not yet.
Relevance: the sector shows the same commercial/failure bifurcation seen in industrial insect farming, but for a different reason — CellulaREvolution’s collapse into administration reflects pre-commercial research-stage capital risk (the company had a real, peer-reviewed scientific platform but ran out of runway before commercialization), not a demand-side “yuck factor” problem. This is a useful contrast to flag: two adjacent alt-protein categories are both distressed in 2026, but for structurally different reasons (capital/scale-ahead-of-demand vs. early-stage research-funding risk).